DE3851497D1 - 2,3-Dihydroergoline zur Steigerung serotonerger Funktionen. - Google Patents

2,3-Dihydroergoline zur Steigerung serotonerger Funktionen.

Info

Publication number
DE3851497D1
DE3851497D1 DE3851497T DE3851497T DE3851497D1 DE 3851497 D1 DE3851497 D1 DE 3851497D1 DE 3851497 T DE3851497 T DE 3851497T DE 3851497 T DE3851497 T DE 3851497T DE 3851497 D1 DE3851497 D1 DE 3851497D1
Authority
DE
Germany
Prior art keywords
dihydroergolines
disclosed
serotonergic functions
increase serotonergic
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3851497T
Other languages
English (en)
Other versions
DE3851497T2 (de
Inventor
Leander Merritt
John Stanley Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE3851497D1 publication Critical patent/DE3851497D1/de
Publication of DE3851497T2 publication Critical patent/DE3851497T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3851497T 1987-08-31 1988-08-22 2,3-Dihydroergoline zur Steigerung serotonerger Funktionen. Expired - Fee Related DE3851497T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/091,462 US4798834A (en) 1987-08-31 1987-08-31 Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement

Publications (2)

Publication Number Publication Date
DE3851497D1 true DE3851497D1 (de) 1994-10-20
DE3851497T2 DE3851497T2 (de) 1995-02-16

Family

ID=22227911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3851497T Expired - Fee Related DE3851497T2 (de) 1987-08-31 1988-08-22 2,3-Dihydroergoline zur Steigerung serotonerger Funktionen.

Country Status (6)

Country Link
US (1) US4798834A (de)
EP (1) EP0306191B1 (de)
JP (1) JPS6468322A (de)
AT (1) ATE111354T1 (de)
DE (1) DE3851497T2 (de)
ES (1) ES2058293T3 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674875A (en) * 1993-05-04 1997-10-07 Eli Lilly And Company Method of blocking human 5-hydroxytryptamine-2 receptors
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
KR101202066B1 (ko) * 2004-09-28 2012-11-15 알러간, 인코포레이티드 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법
WO2018076019A1 (en) * 2016-10-21 2018-04-26 Far Biotech, Inc. Ergot derivative compounds and their use in african sleeping sickness and related disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH344731A (de) * 1956-05-18 1960-02-29 Sandoz Ag Verfahren zur Herstellung von neuen, am Indolstickstoff alkylierten Derivaten der Lysergsäure-Reihe
US3580916A (en) * 1969-02-20 1971-05-25 Lilly Co Eli Hydroxyesters of hexa- and octahydroindoloquinolines
IE41533B1 (en) * 1974-03-14 1980-01-30 Sandoz Ltd Thiomethyl ergolene derivatives
US3992385A (en) * 1975-01-20 1976-11-16 Eli Lilly And Company 2,3-Dihydroergolines
DE2656344A1 (de) * 1975-12-23 1977-07-07 Sandoz Ag Ergolinderivate, ihre verwendung und herstellung
CH628049A5 (en) * 1977-03-25 1982-02-15 Sandoz Ag Process for the preparation of ergolene derivatives
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US4201862A (en) * 1979-03-16 1980-05-06 Eli Lilly And Company 2-Azaergolines and 2-aza-8(or 9)-ergolenes
CH649998A5 (de) * 1982-08-09 1985-06-28 Sandoz Ag Ergolinderivate, ein verfahren zu ihrer herstellung und heilmittel, enthaltend diese ergolinderivate als wirkstoff.
DE3411981A1 (de) * 1984-03-28 1985-10-10 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 2.3-dihydroergolinen
DE3445784A1 (de) * 1984-12-13 1986-06-26 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von ergolin-derivaten

Also Published As

Publication number Publication date
ES2058293T3 (es) 1994-11-01
US4798834A (en) 1989-01-17
DE3851497T2 (de) 1995-02-16
EP0306191A3 (de) 1991-11-06
EP0306191A2 (de) 1989-03-08
ATE111354T1 (de) 1994-09-15
JPS6468322A (en) 1989-03-14
EP0306191B1 (de) 1994-09-14

Similar Documents

Publication Publication Date Title
MX9203543A (es) Medicamento.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IT1197038B (it) Composizione farmaceutica ad attivita' analgesica
DE3870371D1 (de) Herstellung von wasserstoff und kohlenmonoxid.
DE3674906D1 (de) Selbstklemmende medizinische prothese und ihre herstellung.
DE3768546D1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
FI872917A (fi) Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart.
GR3005447T3 (de)
DK0687266T3 (da) Heterocykliske forbindelser og deres fremstilling og anvendelse
ATE111354T1 (de) 2,3-dihydroergoline zur steigerung serotonerger funktionen.
NO173653C (no) Analogifremgangsmaate for fresmstilling av terapeutisk aktive 6-benzoksazinyl-og 6-benzotianzinyl-2,3,4,5-tetrahydropyridazin-3-oner
FR2623806B1 (fr) Esters d'acides 3,6-dihydro-1,5(2h)-pyrimidinecarboxyliques a action therapeutique
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
ATE113207T1 (de) Benzamid gegen kognitive erkrankungen.
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
BR1100435A (pt) Forma medicinal sólida
FR2624008B1 (fr) Prothese extra-thoracique d'assistance ventilatoire moulable par depression
IT1224250B (it) Associzione del depiprazolo con la morfina
IT1258315B (it) Derivati del flavone
DE3872916D1 (de) Herstellung und reinigung eines n,n-diethylaminophenols.
McAlpine Human and divine sleep in the Old Testament

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee